Thirty years of cancer nanomedicine: Success, frustration, and hope

Lucia Salvioni; Maria Antonietta Rizzuto; Jessica Armida Bertolini; Laura Pandolfi; Miriam Colombo; Davide Prosperi

doi:10.3390/cancers11121855

Thirty years of cancer nanomedicine: Success, frustration, and hope

Lucia Salvioni, Maria Antonietta Rizzuto, Jessica Armida Bertolini, Laura Pandolfi, Miriam Colombo, Davide Prosperi

Research output: Contribution to journal › Review article › peer-review

Abstract

Starting with the enhanced permeability and retention (EPR) effect discovery, nanomedicine has gained a crucial role in cancer treatment. The advances in the field have led to the approval of nanodrugs with improved safety profile and still inspire the ongoing investigations. However, several restrictions, such as high manufacturing costs, technical challenges, and effectiveness below expectations, raised skeptical opinions within the scientific community about the clinical relevance of nanomedicine. In this review, we aim to give an overall vision of the current hurdles encountered by nanotherapeutics along with their design, development, and translation, and we offer a prospective view on possible strategies to overcome such limitations.

Original language	English
Article number	1855
Journal	Cancers
Volume	11
Issue number	12
DOIs	https://doi.org/10.3390/cancers11121855
Publication status	Published - Dec 2019
Externally published	Yes

Keywords

Cancer nanomedicine
Clinical translation
EPR effect
Nanoparticles
Nano–bio interactions
Tumor microenvironment

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3390/cancers11121855

Cite this

@article{9a25f73e73ae4e8d8400d01f9d88ec8b,

title = "Thirty years of cancer nanomedicine: Success, frustration, and hope",

abstract = "Starting with the enhanced permeability and retention (EPR) effect discovery, nanomedicine has gained a crucial role in cancer treatment. The advances in the field have led to the approval of nanodrugs with improved safety profile and still inspire the ongoing investigations. However, several restrictions, such as high manufacturing costs, technical challenges, and effectiveness below expectations, raised skeptical opinions within the scientific community about the clinical relevance of nanomedicine. In this review, we aim to give an overall vision of the current hurdles encountered by nanotherapeutics along with their design, development, and translation, and we offer a prospective view on possible strategies to overcome such limitations.",

keywords = "Cancer nanomedicine, Clinical translation, EPR effect, Nanoparticles, Nano–bio interactions, Tumor microenvironment",

author = "Lucia Salvioni and Rizzuto, {Maria Antonietta} and Bertolini, {Jessica Armida} and Laura Pandolfi and Miriam Colombo and Davide Prosperi",

year = "2019",

month = dec,

doi = "10.3390/cancers11121855",

language = "English",

volume = "11",

journal = "Cancers",

issn = "2072-6694",

publisher = "MDPI AG",

number = "12",

}

TY - JOUR

T1 - Thirty years of cancer nanomedicine

T2 - Success, frustration, and hope

AU - Salvioni, Lucia

AU - Rizzuto, Maria Antonietta

AU - Bertolini, Jessica Armida

AU - Pandolfi, Laura

AU - Colombo, Miriam

AU - Prosperi, Davide

PY - 2019/12

Y1 - 2019/12

N2 - Starting with the enhanced permeability and retention (EPR) effect discovery, nanomedicine has gained a crucial role in cancer treatment. The advances in the field have led to the approval of nanodrugs with improved safety profile and still inspire the ongoing investigations. However, several restrictions, such as high manufacturing costs, technical challenges, and effectiveness below expectations, raised skeptical opinions within the scientific community about the clinical relevance of nanomedicine. In this review, we aim to give an overall vision of the current hurdles encountered by nanotherapeutics along with their design, development, and translation, and we offer a prospective view on possible strategies to overcome such limitations.

AB - Starting with the enhanced permeability and retention (EPR) effect discovery, nanomedicine has gained a crucial role in cancer treatment. The advances in the field have led to the approval of nanodrugs with improved safety profile and still inspire the ongoing investigations. However, several restrictions, such as high manufacturing costs, technical challenges, and effectiveness below expectations, raised skeptical opinions within the scientific community about the clinical relevance of nanomedicine. In this review, we aim to give an overall vision of the current hurdles encountered by nanotherapeutics along with their design, development, and translation, and we offer a prospective view on possible strategies to overcome such limitations.

KW - Cancer nanomedicine

KW - Clinical translation

KW - EPR effect

KW - Nanoparticles

KW - Nano–bio interactions

KW - Tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85075680438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075680438&partnerID=8YFLogxK

U2 - 10.3390/cancers11121855

DO - 10.3390/cancers11121855

M3 - Review article

AN - SCOPUS:85075680438

SN - 2072-6694

VL - 11

JO - Cancers

JF - Cancers

IS - 12

M1 - 1855

ER -

Thirty years of cancer nanomedicine: Success, frustration, and hope

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this